红日药业
(300026)
| 流通市值：95.14亿 | | | 总市值：95.23亿 |
| 流通股本：30.01亿 | | | 总股本：30.04亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,187,953,040.26 | 1,130,231,119.07 | 4,941,124,549.57 | 4,148,562,925.07 |
| 营业收入 | 2,187,953,040.26 | 1,130,231,119.07 | 4,941,124,549.57 | 4,148,562,925.07 |
| 二、营业总成本 | 2,043,979,724.16 | 1,031,965,364.51 | 4,626,182,998.81 | 3,909,246,801.58 |
| 营业成本 | 941,121,681.19 | 481,152,433.85 | 2,060,013,994.28 | 1,983,519,089.45 |
| 税金及附加 | 30,602,668.99 | 13,764,454.37 | 64,070,468.08 | 46,508,682.74 |
| 销售费用 | 802,355,382.86 | 398,497,225.45 | 1,882,677,436.4 | 1,433,141,640.1 |
| 管理费用 | 175,700,995.29 | 88,864,460.75 | 405,538,880.54 | 303,293,291.1 |
| 研发费用 | 86,022,860.11 | 45,153,954.98 | 197,738,400.38 | 132,729,098.86 |
| 财务费用 | 8,176,135.72 | 4,532,835.11 | 16,143,819.13 | 10,054,999.33 |
| 其中:利息费用 | 6,926,641.64 | 3,907,449.69 | 19,334,157.54 | 14,434,121.68 |
| 其中:利息收入 | 4,612,862.44 | 2,216,727.41 | 10,842,237.69 | 8,201,461.58 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -10,776,202.06 | -476,095.04 | -3,658,808.4 | -2,874,558.52 |
| 资产处置收益 | 11,039.76 | 10,053.02 | 702,535.55 | 93,112.52 |
| 资产减值损失(新) | -26,146,896.21 | -4,353,030.31 | -166,218,194.84 | -48,133,316.23 |
| 信用减值损失(新) | -8,292,495.94 | -14,248,512.34 | -72,310,155.87 | -45,765,486.42 |
| 其他收益 | 8,516,941.69 | 5,466,063.55 | 30,660,116.43 | 21,640,155.63 |
| 四、营业利润 | 107,285,703.34 | 84,664,233.44 | 104,117,043.63 | 164,276,030.47 |
| 加:营业外收入 | 2,926,823.2 | 1,066,103.51 | 13,564,133.7 | 9,909,639.56 |
| 减:营业外支出 | 2,775,729.37 | 1,456,567.73 | 35,035,098.94 | 32,985,546.61 |
| 五、利润总额 | 107,436,797.17 | 84,273,769.22 | 82,646,078.39 | 141,200,123.42 |
| 减:所得税费用 | 24,526,031 | 15,653,501.55 | 60,422,582.78 | 49,271,434.91 |
| 六、净利润 | 82,910,766.17 | 68,620,267.67 | 22,223,495.61 | 91,928,688.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 82,910,766.17 | 68,620,267.67 | 22,223,495.61 | 91,928,688.51 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 78,088,948.09 | 65,714,810.98 | 18,495,135.72 | 80,762,934.64 |
| 少数股东损益 | 4,821,818.08 | 2,905,456.69 | 3,728,359.89 | 11,165,753.87 |
| 扣除非经常损益后的净利润 | 80,715,327.53 | 64,537,783.54 | 21,575,688.86 | 88,704,796.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.02 | 0.01 | 0.03 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0.01 | 0.03 |
| 八、其他综合收益 | -7,015,750.94 | -3,980,233.43 | -55,625,918.77 | -308,935.97 |
| 归属于母公司股东的其他综合收益 | -7,015,750.94 | -3,980,233.43 | -55,625,918.77 | -308,935.97 |
| 九、综合收益总额 | 75,895,015.23 | 64,640,034.24 | -33,402,423.16 | 91,619,752.54 |
| 归属于母公司股东的综合收益总额 | 71,073,197.15 | 61,734,577.55 | -37,130,783.05 | 80,453,998.67 |
| 归属于少数股东的综合收益总额 | 4,821,818.08 | 2,905,456.69 | 3,728,359.89 | 11,165,753.87 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-21 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |